ArticleNucleic acids research2026
Inducible CRISPRi enables efficient and high-fidelity genome editing in Streptomyces.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Streptomycetes are prolific producers of bioactive natural products, but many of the biosynthetic gene clusters (BGCs) are silent in the laboratory. Genetic manipulation is important to unlock their full potential. CRISPR-Cas-based genome editing has greatly advanced genetic engineering in Streptomyces. However, several challenges remain, including Cas nuclease toxicity, unintended genomic rearrangements, and elimination of the delivery plasmid. Here, we present a novel genome editing strategy that harnesses cumate-inducible CRISPR interference (CRISPRi) to transiently knockdown essential genes such as divIVA or dnaA as counterselectable marker. This enforces loss of the vector backbone, promotes homologous recombination, and yields markerless mutants by loss of the antibiotic resistance cassette during the final recombination step. We demonstrate the versatility of the ICE system (Inducible CRISPRi targeting an Essential gene) by (i) deleting four BGCs in Streptomyces coelicolor M145, (ii) inserting both a promoter and a large BGC, and (iii) introducing precise single-nucleotide substitutions. Furthermore, deletion of the prodigiosin BGC elicited expression of a poorly expressed BGC for prolinolexin lipopeptides in Streptomyces roseifaciens DSM 106196T. Considering that different essential genes may be targeted, we anticipate that inducible CRISPRi-based counterselection may be adaptable to genome editing strategies in a broad range of microbial systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.